Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr12.15 SEK
Change Today -0.25 / -2.02%
Volume 43.0K
OASM On Other Exchanges
As of 11:29 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

oasmia pharmaceutical ab (OASM) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/15 - kr22.90
52 Week Low
10/26/15 - kr11.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oasmia pharmaceutical ab (OASM) Related Businessweek News

No Related Businessweek News Found

oasmia pharmaceutical ab (OASM) Details

Oasmia Pharmaceutical AB (publ) researches, develops, and manufactures drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company’s approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer. It is also developing Paclical for the treatment of metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin, for the treatment of breast cancer; Docecal, a patented formulation of cytostatic docetaxel, for the treatment of breast cancer; and OAS-19 to treat various cancers. Its product candidates for animal health comprise Paccal Vet-CA1, a formulation of paclitaxel, for the treatment of mastocytoma in dogs; and Doxophos Vet for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden.

80 Employees
Last Reported Date: 09/3/15
Founded in 1990

oasmia pharmaceutical ab (OASM) Top Compensated Officers

Co-Founder, Executive Chairman and Member of ...
Total Annual Compensation: kr1.5M
Compensation as of Fiscal Year 2015.

oasmia pharmaceutical ab (OASM) Key Developments

Oasmia Pharmaceutical AB Presents Clinical Data of Cancer Drug Paclical

Oasmia Pharmaceutical AB presented clinical data at the 19th annual Russian Cancer Congress that illustrate the efficacy and benefits of the company's recently approved cancer drug Paclical. The data, which were presented by Russian lead oncologists Professor Tjulandin and Dr. Chekini, were well received by the many oncologists in attendance at the event, positioning the drug for further growth in the Russian market. The company's presentation elaborated on the results from the extensive clinical program indicating that Paclical possesses efficacy which is equal to current standard treatment, albeit with several benefits such as allowing for higher doses, shorter infusion times and no premedication. In addition, a recently published study showed that Paclical is bioequivalent with Abraxane, the current market leader within the segment. Paclical is a water-soluble formulation of paclitaxel and Oasmia's patented excipient, XR-17. Paclitaxel is one of the most widely used anti-cancer substances and is included in the standard treatment of a variety of cancers such as lung cancer, breast cancer and ovarian cancer. Paclical consists of a freeze dried powder dissolved in conventional solution for infusion. In April 2015, Paclical received a marketing authorization for treatment of ovarian cancer in the Russian Federation.

Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-Line Results for Paclical from Head-To-Head Comparison Study with Abraxane

Oasmia Pharmaceutical AB confirmed the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer. The company believes that results from this study strengthen its position for rapid growth among competitors within the oncology sector, including Celgene Corporation and Sorrento Therapeutics Inc. In 2014, Abraxane generated total net sales of $947 million, a 28% increase from the prior year. Further, Sorrento Therapeutics expanded its Cynviloq strategy into multiple cancer indications, potentially receiving over $1 billion compensation for rights.

Oasmia Pharmaceutical Receives Order of $7.5 Million in End-User Value for the Russian Market

Oasmia Pharmaceutical AB announced that it its distribution partner Pharmasyntez, has placed its second order for Paclical, for an end user sale value of $7.5 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OASM:SS kr12.15 SEK -0.25

OASM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OASM.
View Industry Companies

Industry Analysis


Industry Average

Valuation OASM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 62.4x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 55.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OASMIA PHARMACEUTICAL AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at